ReviewFrontiers in pharmacology2022

Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.

Xi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.